Hytera Hosts a Successful Global Partner Summit 2023 in Bali, Indonesia
15.5.2023 13:54:00 EEST | Business Wire | Press release
Hytera Communications (SZSE: 002583), a leading global provider of professional communications technologies and solutions, gathered its distribution, project, and application partners from over 50 countries and regions and successfully held Hytera Global Partner Summit (HGPS) 2023 on May 11th in Bali, Indonesia.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230515005390/en/
Yelin Jiang, CEO of Hytera Group, delivering the keynote speech (Photo: Business Wire)
HGPS serves as a platform for Hytera partners to network with other like-minded professionals, gain insights into the latest trends of the industry, and learn what’s new with Hytera, including new products, solutions, and policies. The year 2023 marks the 30th anniversary of the company; therefore, HGPS 2023 was also a venue for the retrospect and celebration of the common journey shared by Hytera and its partners from across the world.
“The past 30 years have seen Hytera rose against numerous challenges and evolved from a product provider to a technology and solution provider. Now we are one of the leading companies in mission-critical and business-critical communications. Our talented engineers working in 8 R&D facilities across the world are the source of our confidence in future growth,” said Yelin Jiang, CEO of Hytera Group, in the keynote speech. “In 2022, Hytera released many innovative new products across multiple product series such as DMR radios , MCS & PoC radios, and body cameras. The new-generation H Series DMR radio was an instant success in the market.”
Thomas Lynch, executive research director of Omdia, was present to share the latest industry trends and developments with attendees, providing insights into the ever-changing industry landscape. According to Omdia’s analysis, in response to the market demands for data-rich features, Mission Critical Communications are moving towards a hybrid approach: keeping trusted LMR technology, such as TETRA, DMR, PDT for the indispensable voice communication in extreme situations and empowering the additional services and features with integrated LTE Broadband solutions. This is manifested in Hytera’s multi-front product development strategy.
Fully leveraging the venue of HGPS, Hytera brought regional partners into a global perspective with product solution deep dives and partners’ case studies. At the exhibition area, a complete portfolio of Hytera products and solutions were showcased, including TETRA Radios and Systems, DMR Radios and Systems, MCS & PoC Radios and Solutions , Body Camera Solutions , Multimedia Communication Platform, Control Room Solutions, 4G&5G Systems, and Fast Deployment Solutions. HGPS2023 invited some of Hytera ecosystem partners to showcase their value-added applications on top of Hytera products and they brought solutions such as encryptions, dispatching, satellite connectivity, and emergency coordination.
The Summit concluded on a high note with the Hytera 30th Anniversary and Awarding Ceremony, which acknowledged the performance and progress of partners in the year 2022. Golden Loyalty Awards was specially set up for HGPS2023 to celebrate the long-term partnership with and loyalty to the Hytera brand in the past three decades.
About Hytera
Hytera Communications Corporation Limited (SZSE: 002583) is a leading global provider of professional communications technologies and solutions. With voice, video and data capabilities, we provide faster, safer, and more versatile connectivity for business and mission critical users. We make the world more efficient and safer by enabling our customers to achieve more in both daily operations and emergency response. Learn more at https://www.hytera.com/en/home.html.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230515005390/en/
Contact information
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom